The global flow cytometry market size was estimated at USD 4,684.2 million in 2024 and is projected to reach USD 7,013.1 million by 2030, growing at a CAGR of 8.41% from 2025 to 2030. A major driver behind this upward trend is the increasing incidence of serious health conditions such as cancer, immunodeficiency disorders, and infectious diseases, which necessitate precise diagnostic and monitoring tools like flow cytometry.
In parallel, the market is further boosted by substantial investments in research and development across various sectors including biotechnology, life sciences, and biopharmaceutical research. These investments have resulted in enhanced demand for advanced flow cytometry instruments that can support complex biological analyses and drug development processes. For example, in February 2023, Cytek Biosciences revealed plans to acquire the imaging and flow cytometry business from DiaSorin, a move intended to strengthen its presence and expand its market share globally.
Flow cytometry plays a vital role in the clinical diagnosis of cancer and immunodeficiency diseases. The rising prevalence of these disorders is expected to continue fueling market growth in the foreseeable future. Moreover, the side effects linked to conventional cancer treatments such as chemotherapy and radiation therapy have led healthcare providers to increasingly prefer autologous and allogeneic stem cell therapies. These therapies rely heavily on flow cytometry for evaluating cell populations and ensuring treatment efficacy, thereby driving additional demand.
To put the significance of this market into perspective, the American Cancer Society reported that roughly 1.9 million new cancer cases were diagnosed in the United States in 2022, with close to 600,000 deaths resulting from the disease. This growing cancer burden highlights the urgent need for sophisticated diagnostic technologies like flow cytometry, which provides detailed immune cell profiling and supports ongoing treatment monitoring, improving patient outcomes.
Key Market Trends Insights:
• In 2024, North America emerged as the leading region in the global flow cytometry market, capturing the largest revenue share of 41.35%. This dominant position highlights the region’s strong foothold, driven by factors such as advanced healthcare infrastructure, high adoption of cutting-edge diagnostic technologies, and substantial investments in biotechnology research.
• Focusing on the United States, the flow cytometry market is anticipated to grow at a robust compound annual growth rate (CAGR) over the period from 2024 to 2030. This significant growth is expected due to increasing incidences of diseases requiring flow cytometry diagnostics, supportive government initiatives, and continuous advancements in medical research and healthcare facilities.
• When segmented by product type, the instrument segment took the lead, accounting for the largest revenue share of 35.30% in 2024. This reflects the growing demand for sophisticated flow cytometry instruments that enable precise cellular analysis, which are essential in clinical diagnostics and research applications.
• Moreover, based on technology, the cell-based segment dominated the market, commanding a substantial revenue share of 76.16% in 2024. This dominance can be attributed to the widespread use of cell-based flow cytometry technologies in a variety of applications, including immunophenotyping, cancer diagnostics, and stem cell research, due to their accuracy and efficiency in analyzing cellular characteristics.
Order a free sample PDF of the Flow Cytometry Market Intelligence Study, published by Grand View Research.
Market Size Forecast:
• 2024 Market Size: USD 4,684.2 Million
• 2030 Projected Market Size: USD 7,013.1 Million
• CAGR (2025-2030): 8.41%
• North America: Largest market in 2024
Key Companies Market Share Insights:
Established and well-recognized companies in the flow cytometry industry, including Danaher, BD, Sysmex Corp., Agilent Technologies, Inc., Apogee Flow Systems Ltd., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Stratedigm, Inc., Miltenyi Biotec, Cytek Biosciences, and Sony Group Corporation (Sony Biotechnology Inc.), are strategically positioning themselves to achieve sustained growth in this competitive market. These leading players are heavily investing in continuous research and development efforts to innovate and enhance their flow cytometry technologies. Additionally, they are actively pursuing strategic partnerships and acquisitions to strengthen their market presence and expand their offerings. By consistently broadening their product portfolios and leveraging their extensive industry experience and established market foothold, these companies aim to maintain and reinforce their leadership roles while staying adaptive to evolving trends and demands within the flow cytometry landscape.
At the same time, newer and emerging companies in the flow cytometry sector are proactively engaging in strategic initiatives to carve out their own market positions. These emerging players focus on innovation by developing cutting-edge products that address specific unmet needs within the market. Furthermore, they pursue strategic collaborations and partnerships to accelerate growth and market access, alongside expanding into new geographic and application areas. By adopting these approaches, emerging participants strive to take advantage of the rising global demand for advanced flow cytometry solutions and establish themselves as key contributors in the industry’s future growth trajectory.
Key Players
• Danaher
• BD
• Sysmex Corporation
• Agilent Technologies, Inc.
• Apogee Flow Systems Ltd.
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Stratedigm, Inc.
• Miltenyi Biotec
• Cytek Biosciences
• Sony Group Corporation (Sony Biotechnology Inc.)
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion:
The flow cytometry market is experiencing significant growth driven by rising prevalence of diseases like cancer and immunodeficiency disorders, along with increased investment in biotech and life sciences research. Key players are focusing on innovation, strategic partnerships, and acquisitions to strengthen their market positions. The technology’s critical role in diagnostics and treatment monitoring continues to boost demand globally.
